Effects of Whole-body Electrostimulation on Patients With Chronic Kidney Disease
NCT Number: NCT06502522
Status: NOT_YET_RECRUITING
Study Type: INTERVENTIONAL
Phases: NA
Conditions: Renal Insufficiency, Chronic
Interventions: OTHER: Whole-body electrical stimulation
Sponsor: Federal University of Health Science of Porto Alegre
Collaborators: Leonhardt Ventures LLC
Sex: ALL
Age: ADULT, OLDER_ADULT
Enrollment: 30
Study Design: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2024-08-01
Completion Date: 2025-03-01

Summary:
Chronic kidney disease (CKD) consists of kidney damage, with consequent progressive and irreversible loss of kidney function. In the early stages of the disease, a reduction in circulating levels of the α-klotho protein is already observed, which is related to worsening renal function. Therapeutic strategies that increase serum levels of α-klotho may be of great value in the treatment of CKD. Electrical stimulation contributes to the reduction of reactive oxygen species, DNA damage and improves the effectiveness rate of dialysis, suggesting a systemic effect in patients with terminal CKD. The objective of this study is to evaluate the effects of whole body electrical stimulation on renal function and physical capacity in patients with CKD not dependent on dialysis.

Primary Outcome Measures: Change in kidney function, Change in kidney function will be assessed by alpha klotho protein dosage, Baseline, after 4 and 8 weeks|Change in kidney function, Change in kidney function will be assessed by serum creatinine measurement, Baseline, after 4 and 8 weeks
Secondary Outcome Measures: Change in inflammatory profile, Change in inflammatory profile will be assessed by measurement of interleukin 6 (IL6), Baseline, after 4 and 8 weeks|Change in inflammatory profile, Change in inflammatory profile will be assessed by measurement of interleukin 10 (IL10), Baseline, after 4 and 8 weeks|Change in inflammatory profile, Change in inflammatory profile will be assessed by measurement of tumor necrosis factor alpha (TNF-a), Baseline, after 4 and 8 weeks|Change in well-being levels, Change in well-being levels will be assessed by serum beta-endorphin dosage, Baseline, after 4 and 8 weeks|Change in muscle damage levels, Change in muscle damage levels will be assessed by serum creatine kinase (CK) measurement, Baseline, after 4 and 8 weeks|Change in isometric muscle strength of the quadriceps, Change in isometric muscle strength of the quadriceps will be assessed by dynamometry, Baseline and 8 weeks|Change in handgrip muscle strength, Change in handgrip muscle strength will be assessed by dynamometry, Baseline and 8 weeks|Change in lower limb muscle strength, Change in lower limb muscle strength will be assessed using the 10-repetition sit-and-stand test (10SST), Baseline and 8 weeks|Change in functional capacity, Change in functional capacity will be assessed through the distance covered in the six-minute walk test (6MWT), Baseline and 8 weeks|Change in sleep quality, Change in sleep quality will be assessed by the Pittsburgh Sleep Quality Index (PSQI).The score ranges from 0 to 21. Lower scores reflect worse sleep quality., Baseline and 8 weeks|Change in quality of life, Change in quality of life will be assessed using the EuroQoL-5D (EQ-5D) questionnaire, Baseline and 8 weeks